Phase 2, Multi-Arm Study of Niraparib Administered Alone and in Combination With PD-1 Inhibitor in Patients With Non-Small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2018
At a glance
- Drugs Niraparib (Primary)
- Indications Lung cancer; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms JASPER
- Sponsors TESARO
- 27 Feb 2018 According to a TESARO media release, initial data from this trial is expected in 2H 2018
- 08 Feb 2018 Planned primary completion date changed from 1 May 2018 to 1 Dec 2018.
- 09 Oct 2017 Status changed from planning to recruiting.